Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

NCT01006265 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

464

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: ACT-128800 Dose 1
DRUG: Placebo
DRUG: ACT-128800 Dose 2
DRUG: ACT-128800 Dose 3

Sponsor

Actelion